HAE – Haemonetics Corporation

Haemonetics Corporation

HAE

$68.27

Name : Haemonetics Corporation

Sector : Healthcare

Industry: Medical Devices

Mark. Cap: $3,266,405,120.00

EPSttm : 3.31

Haemonetics Corporation

$68.27

1.27%

$0.875

Float Short %

8.77

Margin Of Safety %

-9

Put/Call OI Ratio

3.3

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

0.71

Price

69.14

Target Price

91.1

Analyst Recom

1.45

Performance Q

12.35

Relative Volume

0.57

Beta

0.37

Ticker: HAE

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-04-14	HAE	59.36	2.46	4.00	10365
2025-04-15	HAE	58.3	2.46	417.92	10365
2025-04-16	HAE	56.88	3.14	354.33	12441
2025-04-17	HAE	57.13	2.41	999.99	10264
2025-04-18	HAE	57.17	2.41	999.99	10264
2025-04-21	HAE	57.03	3.33	0.00	9214
2025-04-22	HAE	59.18	3.32	94.31	9219
2025-04-23	HAE	60.26	3.99	0.00	10735
2025-04-24	HAE	61.92	3.97	0.00	10746
2025-04-25	HAE	62.51	3.8584269662921	7.5	10810
2025-04-28	HAE	62.64	3.8588764044944	0.33333333333333	10811
2025-04-29	HAE	64.02	3.86	4.04	10812
2025-04-30	HAE	62.96	3.37	0.60	13547
2025-05-01	HAE	62.98	2.98	0.22	14344
2025-05-02	HAE	63.86	2.98	11.86	14347
2025-05-05	HAE	62.55	3.06	1.44	14559
2025-05-06	HAE	63.6	3.06	6.94	14578
2025-05-07	HAE	64.18	3.07	93.55	14715
2025-05-08	HAE	68.09	3.61	0.39	16771
2025-05-09	HAE	68.2	3.37	1.26	17124
2025-05-12	HAE	70.3	3.37	0.03	17126
2025-05-13	HAE	69.09	3.30	0.47	17217
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-04-14	HAE	59.42	35.6	67.3	4.55
2025-04-15	HAE	58.30	35.6	65.7	4.55
2025-04-16	HAE	56.90	35.6	64.7	4.55
2025-04-17	HAE	57.17	35.6	70.3	4.55
2025-04-18	HAE	57.17	35.6	69.3	4.55
2025-04-21	HAE	57.01	35.6	68.8	4.55
2025-04-22	HAE	59.15	35.6	76.5	4.55
2025-04-23	HAE	60.34	35.6	73.2	4.55
2025-04-24	HAE	61.91	35.6	74.3	4.55
2025-04-25	HAE	62.51	35.6	71.1	4.55
2025-04-28	HAE	62.64	35.6	69.7	4.55
2025-04-29	HAE	63.97	35.6	73.4	4.55
2025-04-30	HAE	63.02	35.6	66.4	4.55
2025-05-01	HAE	62.99	35.6	69.2	4.55
2025-05-02	HAE	63.85	35.6	72.0	4.55
2025-05-05	HAE	62.46	35.6	65.1	4.55
2025-05-06	HAE	63.57	35.6	72.7	4.55
2025-05-07	HAE	64.25	35.6	71.4	4.55
2025-05-08	HAE	68.02	35.6	80.7	4.55
2025-05-09	HAE	68.20	4.8	69.9	4.89
2025-05-12	HAE	70.23	4.8	75.2	4.89
2025-05-13	HAE	69.14	4.8	66.3	4.89
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-04-14	HAE	0.00	-3.02	9.12
2025-04-15	HAE	0.00	-3.02	9.12
2025-04-16	HAE	0.00	-3.02	9.12
2025-04-17	HAE	0.00	-3.02	9.12
2025-04-18	HAE	0.00	-3.02	9.12
2025-04-21	HAE	0.00	-3.32	9.12
2025-04-22	HAE	0.00	-3.32	9.12
2025-04-23	HAE	0.00	-3.32	9.12
2025-04-24	HAE	0.00	-3.32	9.12
2025-04-25	HAE	0.00	-3.32	9.12
2025-04-28	HAE	0.00	-2.56	8.92
2025-04-29	HAE	0.00	-2.56	8.92
2025-04-30	HAE	0.00	-2.56	8.92
2025-05-01	HAE	0.00	-2.56	8.92
2025-05-02	HAE	0.00	-2.56	8.92
2025-05-05	HAE	0.00	-2.22	8.92
2025-05-06	HAE	0.00	-2.22	8.92
2025-05-07	HAE	0.00	-2.22	8.92
2025-05-08	HAE	0.00	-2.22	8.92
2025-05-09	HAE	0.00	-2.22	8.92
2025-05-12	HAE	0.00	-1.06	8.77
2025-05-13	HAE	0.00	-1.06	8.77
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

1.07

Avg. EPS Est. Next Quarter

1.18

Insider Transactions

Institutional Transactions

-1.06

Beta

0.37

Average Sales Estimate Current Quarter

312

Average Sales Estimate Next Quarter

327

Fair Value

63.05

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

51.4

Max Drawdown 5-Year %

-68.6

Target Price

91.1

P/E

20.85

Forward P/E

12.26

PEG

1.84

P/S

2.55

P/B

3.83

P/Free Cash Flow

24.38

EPS

3.32

Average EPS Est. Cur. Y

4.89

EPS Next Y. (Est.)

5.6

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

12.32

Relative Volume

0.57

Return on Equity vs Sector %

-9.3

Return on Equity vs Industry %

-3.7

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.04

EBIT Estimation

66.3

Haemonetics Corporation

Sector: Healthcare

Industry: Medical Devices

Employees:

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

stock quote shares HAE – Haemonetics Corporation Stock Price stock today

news today HAE – Haemonetics Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch HAE – Haemonetics Corporation yahoo finance google finance

stock history HAE – Haemonetics Corporation invest stock market

stock prices HAE premarket after hours

ticker HAE fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

HAE – Haemonetics Corporation

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: HAE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y